Last reviewed · How we verify
Seasonal trivalent inactivated influenza vaccine
The vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus, providing protection against seasonal flu infection.
The vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | Seasonal trivalent inactivated influenza vaccine |
|---|---|
| Also known as | VaxiGrip, Vaxigrip |
| Sponsor | PATH |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The inactivated vaccine contains killed influenza virus particles from three circulating strains (typically two A subtypes and one B type). When administered, it triggers both humoral (antibody) and cell-mediated immune responses without causing infection. The induced antibodies bind to viral surface proteins, preventing viral attachment and entry into host cells, while T-cell responses provide additional protection.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (PHASE3)
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
- Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients (NA)
- Effects of Aging on Primary and Secondary Vaccine Responses (PHASE1)
- Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: